Stock SANION SANA AB
Add to a list
To use this feature you must be a member
Log inSign up

Ratings SANA AB

Equities

SANION

SE0005794617

Market Closed - Nasdaq Stockholm
Other stock markets
 11:29:55 2024-06-04 am EDT 		5-day change 1st Jan Change
2.475 SEK -1.20% Intraday chart for SANA AB +22.52% -38.28%
May. 29 Saniona AB Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
May. 08 Terna in first quarter increases profit and revenues by double digits AN

Summary

  • The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company has insufficient levels of profitability.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
SANA AB Stock SANA AB
-38.28% 26.75M -
D+
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+16.73% 121B
B+
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+13.04% 107B
B+
BIONTECH SE Stock BioNTech SE
-5.80% 24.82B
B+
ARGENX SE Stock argenx SE
+1.69% 22.48B
B
GENMAB A/S Stock Genmab A/S
-10.09% 18.32B
A-
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-40.52% 16.33B
A-
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.00% 15.31B
B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+1.18% 14.08B
C+
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+24.18% 11.74B
C+
Investor Rating
-
Trading Rating
-
ESG Refinitiv

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
-
4 months EPS revision
-

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. SANION Stock
  4. Ratings SANA AB